|
Q1 FY2027
As of Aug 31, 2026
|
Q4 FY2026
As of May 31, 2026
|
Q3 FY2026
As of Feb 28, 2026
|
Q2 FY2026
As of Nov 30, 2025
|
Q1 FY2026
As of Aug 31, 2025
|
Q4 FY2025
As of May 31, 2025
|
Q3 FY2025
As of Feb 28, 2025
|
Q2 FY2025
As of Nov 30, 2024
|
Q1 FY2025
As of Aug 31, 2024
|
Q4 FY2024
As of May 31, 2024
|
Q3 FY2024
As of Feb 29, 2024
|
Q2 FY2024
As of Nov 30, 2023
|
Q1 FY2024
As of Aug 31, 2023
|
Q4 FY2023
As of May 31, 2023
|
Q3 FY2023
As of Feb 28, 2023
|
Q2 FY2023
As of Nov 30, 2022
|
Q1 FY2023
As of Aug 31, 2022
|
Q4 FY2022
As of May 31, 2022
|
Q3 FY2022
As of Feb 28, 2022
|
Q2 FY2022
As of Nov 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Prepaid service fees | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Operating leases right-of-use asset | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders' Deficit | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities and compensation | ||||||||||||||||||||
| Accrued interest on convertible notes | ||||||||||||||||||||
| Accrued dividends on convertible preferred stock | ||||||||||||||||||||
| Series C Convertible Preferred Stock | ||||||||||||||||||||
| Series D Convertible Preferred Stock | ||||||||||||||||||||
| Total accrued dividends on convertible preferred stock | ||||||||||||||||||||
| Operating leases | ||||||||||||||||||||
| Current portion of long-term convertible notes payable | ||||||||||||||||||||
| Derivative liability - equity instruments | ||||||||||||||||||||
| Private placement of shares and warrants | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Convertible notes payable | ||||||||||||||||||||
| Accrued interest on convertible notes | ||||||||||||||||||||
| Operating leases | ||||||||||||||||||||
| Other liabilities (Note 10) | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' deficit: | ||||||||||||||||||||
| Preferred stock | ||||||||||||||||||||
| Common stock, $0.001 par value; 2,250,000 shares authorized; 1,454,639 and 1,373,803 issued, and 1,454,353 and 1,373,517 outstanding at August 31, 2026 and May 31, 2026, respectively | ||||||||||||||||||||
| Treasury stock, $0.001 par value; 286 shares at August 31, 2026 and May 31, 2026 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' deficit | ||||||||||||||||||||
| Total liabilities and stockholders' deficit | ||||||||||||||||||||
Loading...
